Evonetix Ltd, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. The Company has raised $30 million USD (£23 million GBP) in this round, which was led by new investor Foresite Capital.
Evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations.
Telephone: +44 (0)1223 930 300
Address: 9a Coldham's Business Park Norman Way Cambridge
Post Code: CB1 3LH
Country: United Kingdom
Membership Type: Corporate 21-50